GENE ONLINE|News &
Opinion
Blog

2020-09-16| Technology

Exploring RNA Splicing as a Potential New Drug Avenue for Parkinson’s Disease

by Tulip Chakraborty
Share To
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. Approximately 60,000 people get diagnosed with PD in the United States alone and around 10 million people live with this motor disorder.
With the aging population of the world increasing, this age-dependent neurodegenerative disease is a substantial socioeconomic burden. Further complicating the situation is the lack of disease-modifying therapy, while the treatments available can only take care of the symptoms.
RNA mis-splicing as a potential mechanism of neurodegeneration.
The study by Boussaad et al. demonstrated that a mutation in one of the disease-causing gene, DJ-1 leads to mis-splicing of DJ-1.

GO Prime with only $1.49 now

LATEST
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
Exosomes: The Small Couriers Moving Beyond Traditional Drug Delivery
2025-04-17
Trump Administration’s CDC Layoffs Shutter STD Lab, Sending Ripples Through Biotech and Global Health
2025-04-17
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
NIH Facing $20 Billion Budget Cut and Potential Consolidation in 2026
2025-04-16
Trump Administration Budget Proposal Includes $20 Billion Cut to NIH by 2026 and Agency Reorganization
2025-04-16
Robert F. Kennedy Jr.’s Proposed Budget Prioritizes Public Health, Environmental Protection, and Healthcare Reform
2025-04-16
EVENT
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
Scroll to Top